GAMA
CLVS

Graticule Asia Macro Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Graticule Asia Macro Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-27,700
Closed -$2.28M – 101
2017
Q3 		$2.28M Buy
27,700
+7,700
+39% +$610K 0.1% 77
2017
Q2 		$1.87M Sell
20,000
-114,884
-85% -$7.03M 0.09% 93
2017
Q1 		$8.59M Buy
134,884
+94,477
+234% +$5.74M 0.5% 53
2016
Q4 		$1.79M Buy
40,407
+9,357
+30% +$329K 0.22% 74
2016
Q3 		$1.12M Buy
+31,050
New +$666K 0.08% 80

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return